Drug intelligence / Profile preview

AIG-Onco4

Development stage: Discontinued
Lead developer: AIGEN Sciences
Modality: Small Molecules

Overview

AIG-Onco4 is a small molecule drug candidate that was initially developed by Aigen Sciences. It was being investigated for the treatment of neoplasms, with a particular focus on solid tumors. The drug reached the discovery stage in development but has since been discontinued and is no longer actively pursued. Specific details regarding its mechanism of action, molecular targets, or further pharmacological properties have not been disclosed publicly[1][2].

Beyond the preview

Go deeper on AIG-Onco4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIG-Onco4.

Explore the full profile